Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb:67:8-13.
doi: 10.1016/j.breast.2022.12.004. Epub 2022 Dec 15.

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

Fausto Petrelli  1 , Valentina Bertaglia  2 , Maria Chiara Parati  3 , Karen Borgonovo  3 , Pushpamali De Silva  4 , Andrea Luciani  3 , Silvia Novello  5 , Mario Scartozzi  6 , Leisha A Emens  7 , Cinzia Solinas  6
Affiliations

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis

Fausto Petrelli et al. Breast. 2023 Feb.

Abstract

The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients. This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone.

Keywords: Adjuvant therapy; Capecitabine; Network meta-analysis; Prognosis; Resected triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None declared.

Figures

Fig. 1
Fig. 1
Flow diagram of included studies.
Fig. 2a
Fig. 2a
Treatment ranking and relative effect for overall survival of various modern regimens compared to anthracycline-based chemotherapy.
Fig. 2b
Fig. 2b
Network diagram of overall survival comparison.
Fig. 3a
Fig. 3a
Treatment ranking and relative effect for disease-free survival of various modern regimens compared to anthracycline-based chemotherapy.
Fig. 3b
Fig. 3b
network diagram of disease-free survival comparison.
See this image and copyright information in PMC

References

    1. Bianchini G., Balko J.M., Mayer I.A., Sanders M.E., Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. Nov. 2016 Nov;13(11):674–690. doi: 10.1038/nrclinonc.2016.66. - DOI - PMC - PubMed
    1. Masuda N., Lee S.-J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017 Jun;376(22):2147–2159. doi: 10.1056/NEJMoa1612645. - DOI - PubMed
    1. Wang X., Wang S.S., Huang H., etal Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325(1):50–58. doi: 10.1001/jama.2020.23370. - DOI - PMC - PubMed
    1. Burstein H.J., Curigliano G., Thürlimann B., et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–1235. - PMC - PubMed
    1. Poggio F., Bruzzone M., Ceppi M., et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7) doi: 10.1093/annonc/mdy127. 1497-08. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources